Ignite Creation Date:
2024-05-06 @ 7:55 PM
Last Modification Date:
2024-10-26 @ 3:16 PM
Study NCT ID:
NCT06180785
Status:
RECRUITING
Last Update Posted:
2023-12-22
First Post:
2022-09-06
Brief Title:
Performance Evaluation of the Biological Diagnosis of HIT
Sponsor:
University Hospital Strasbourg France
Organization:
University Hospital Strasbourg France
Study Overview
Official Title:
Performance Evaluation of the Biological Diagnosis of Heparin-induced Thrombocytopenia HIT
Status:
RECRUITING
Status Verified Date:
2023-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
HIT
Brief Summary:
Heparin-induced thrombocytopenia HIT is a severe complication of heparin therapy with a non-negligible incidence estimated at 26 of unfractionated heparin treatments and 02 of low molecular weight heparin treatments It is generally secondary to the appearance of IgG antibodies directed against the platelet factor 4 PF4 - heparin complex These antibodies once bound to this complex are likely to activate platelets the thrombotic risk generated can be potentially fatal
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None